Journal: Molecular Metabolism

Article Title: Membrane-associated ring–CH–type finger 2 protects against metabolic dysfunction-associated fatty liver disease by targeting fatty acid synthase

doi: 10.1016/j.molmet.2025.102137

Figure Lengend Snippet: Overexpression of hepatic MARCH2 ameliorates MAFLD in ob/ob mice. (A) The rAAV8 with TBG promoter-driven MARCH2 (AAV-MARCH2) or GFP (AAV-GFP) were delivered by tail vein injection to 8-week-old ob/ob mice and fed with a chow diet for another 7 weeks. This schema diagram was created by Figdraw (authorization code: TTPIO86bdd). Body weight (B), morphology of the mice and liver (C), GTT (D), ITT (E), area under curve(AUC) of GTT(F), AUC of ITT(G), liver weight (H), ratios of liver weight to body weight (I), liver HE staining (J), liver Oil Red O staining (K), liver TG contents (L), liver MARCH2 mRNA expression (M), and FASN protein levels (N) of AAV-MARCH2 and AAV-GFP mice were detected. n = 6–8 mice per group, and the data were expressed as Mean ± SEM. Two-tailed unpaired student’s t -test were applied.

Article Snippet: The rAAV8 with thyroxine binding globulin (TBG) promoter-driven MARCH2 coding sequence (AAV-MARCH2) or GFP control (AAV-GFP) were generated by GenePharma (Shanghai, China).

Techniques: Over Expression, Injection, Staining, Expressing, Two Tailed Test

Journal: The Journal of Clinical Investigation

Article Title: AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes

doi: 10.1172/JCI133051

Figure Lengend Snippet: (A) WT mice were fed a HiAD for 14 weeks. At week 7, a group of mice were injected with AAV8-TBG-Nrf2 (5 × 1011 GC/mouse) or AAV8-GFP as a control. There was a decrease in serum and liver AGEs in the AAV8-Nrf2–injected group. (B) Expression of Ager1 and the NRF2 targets Gstp1 and Hmox1 increased following AAV8-Nrf2 injection. (C) Expression of transcripts reflecting inflammation — Mcp1, Tnfa, and Il1b — was also significantly reduced. (D) Expression of Col1a1 and Tgfb was significantly decreased by Nrf2 transduction. Data are presented as the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA with Tukey’s post hoc test.

Article Snippet: A group of control ( fl/fl) mice fed a high-AGE diet were injected with 5 × 10 11 genome copies (GC) AAV8 thyroxine-binding globulin (TBG) promoter- Nrf2 or control GFP (Vector Biolabs) via the tail vein at 7 weeks and were then euthanized 7 weeks after injection (14 weeks on the diet).

Techniques: Injection, Expressing, Transduction